Jpmorgan Chase & CO Tarsus Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 440,167 shares of TARS stock, worth $24.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

440,167

Previous 20,110 2088.8%

Holding current value

$24.2 Million

Previous $546,000 2551.47%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Dec 26, 2024	BUY	$21.54 - $34.6 $9.05 Million - $14.5 Million	420,057 Added 2088.8%	440,167 $14.5 Million
Q3 2024 Nov 08, 2024	BUY	$21.54 - $34.6 $9.05 Million - $14.5 Million	420,057 Added 2088.8%	440,167 $14.5 Million
Q2 2024 Dec 26, 2024	SELL	$25.17 - $38.73 $10.6 Million - $16.3 Million	-420,057 Reduced 95.43%	20,110 $546,000
Q2 2024 Aug 12, 2024	SELL	$25.17 - $38.73 $836,373 - $1.29 Million	-33,229 Reduced 62.3%	20,110 $546,000
Q1 2024 Dec 26, 2024	SELL	$19.61 - $39.22 $7.59 Million - $15.2 Million	-386,828 Reduced 87.88%	53,339 $1.94 Million
Q1 2024 May 10, 2024	BUY	$19.61 - $39.22 $544,550 - $1.09 Million	27,769 Added 108.6%	53,339 $1.94 Million
Q4 2023 Dec 26, 2024	SELL	$12.98 - $20.73 $5.38 Million - $8.59 Million	-414,597 Reduced 94.19%	25,570 $517,000
Q4 2023 Feb 12, 2024	BUY	$12.98 - $20.73 $45,014 - $71,891	3,468 Added 15.69%	25,570 $517,000
Q3 2023 Nov 14, 2023	BUY	$14.75 - $24.62 $42,819 - $71,471	2,903 Added 15.12%	22,102 $392,000
Q2 2023 Aug 11, 2023	BUY	$11.57 - $19.63 $48,941 - $83,034	4,230 Added 28.26%	19,199 $346,000
Q1 2023 May 18, 2023	BUY	$11.92 - $16.27 $167,809 - $229,049	14,078 Added 1580.02%	14,969 $188,000
Q1 2023 May 11, 2023	SELL	$11.92 - $16.27 $124,683 - $170,184	-10,460 Reduced 92.15%	891 $11,000
Q4 2022 Feb 13, 2023	BUY	$14.12 - $18.72 $18,483 - $24,504	1,309 Added 13.04%	11,351 $167,000
Q3 2022 Nov 14, 2022	BUY	$14.08 - $18.5 $4,913 - $6,456	349 Added 3.6%	10,042 $172,000
Q2 2022 Aug 11, 2022	BUY	$11.08 - $19.08 $63,588 - $109,500	5,739 Added 145.14%	9,693 $142,000
Q1 2022 May 11, 2022	SELL	$14.49 - $24.28 $2.47 Million - $4.15 Million	-170,782 Reduced 97.74%	3,954 $67,000
Q4 2021 Feb 10, 2022	BUY	$21.21 - $29.68 $3.64 Million - $5.09 Million	171,499 Added 5298.08%	174,736 $3.93 Million
Q3 2021 Nov 12, 2021	BUY	$21.45 - $29.22 $69,433 - $94,585	3,237 New	3,237 $70,000

Others Institutions Holding TARS

# of Institutions

170

Shares Held

43.3M

Call Options Held

484K

Put Options Held

4.1K

View Full List

About Tarsus Pharmaceuticals, Inc.

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $1.47B
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

More about TARS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Tarsus Pharmaceuticals, Inc. Transaction History